Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
To evaluate the efficacy and safety of Xinlikang capsule in the treatment of cancer-related fatigue (CRF) and peripheral blood lymphocytes in patients with diffuse large B-cell lymphoma (DLBCL) who achieved complete remission (CR) after all courses of chemotherapy-containing regimens
Epistemonikos ID: b605b0c3828276d21c20c372c38015bc3b82fd19
First added on: Jul 25, 2025